Redwood Investment Management LLC acquired a new position in shares of Bristol Myers Squibb Company (NYSE:BMY – Free Report) in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 15,992 shares of the biopharmaceutical company’s stock, valued at approximately $921,000.
A number of other large investors have also recently bought and sold shares of BMY. Parvin Asset Management LLC purchased a new position in Bristol Myers Squibb in the 2nd quarter valued at about $1,109,000. Proficio Capital Partners LLC purchased a new stake in shares of Bristol Myers Squibb during the second quarter worth about $360,000. Stonebridge Capital Management Inc. acquired a new position in shares of Bristol Myers Squibb in the second quarter valued at approximately $779,000. Pure Financial Advisors LLC acquired a new position in shares of Bristol Myers Squibb in the second quarter valued at approximately $1,295,000. Finally, Transamerica Financial Advisors LLC purchased a new position in shares of Bristol Myers Squibb during the second quarter valued at approximately $1,521,000. Institutional investors and hedge funds own 76.41% of the company’s stock.
Key Stories Impacting Bristol Myers Squibb
Here are the key news stories impacting Bristol Myers Squibb this week:
- Positive Sentiment: The FDA approved Zenbexus (iberdomide), BMY’s first-in-class CELMoD therapy, for adults with relapsed or refractory multiple myeloma in combination with Darzalex and dexamethasone. The approval adds a potential oncology growth driver and expands BMY’s treatment portfolio in a major cancer market. New FDA Approval Gives Bristol-Myers Squibb Another Potential Oncology Growth Catalyst
- Positive Sentiment: Zenbexus received accelerated approval based on improved minimal residual disease-negative complete response rates. As the first approved CELMoD therapy in this setting, it could strengthen BMY’s competitive position in multiple myeloma, although continued approval depends on confirmatory evidence. Zenbexus First-in-Class CELMoD Approval
- Positive Sentiment: BMY is extending clinical development of deucravacitinib, signaling longer-term ambitions in autoimmune diseases and potentially broadening its growth pipeline beyond oncology. Bristol Myers Squibb Extends Deucravacitinib Program
- Neutral Sentiment: Camzyos continues to gain momentum, but its ability to offset patent pressures on older products depends partly on an upcoming FDA decision regarding adolescent use and competition from rival heart drugs. Can Camzyos Growth Offset Bristol Myers Patent Pressures?
- Negative Sentiment: BMY ended its Cellares partnership after concluding that the Cell Shuttle platform could not support commercial-scale manufacturing of Breyanzi. The decision raises questions about manufacturing capacity and the pace of Breyanzi growth, despite avoiding further spending under the agreement valued at up to $380 million. Bristol-Myers Squibb’s Cellares Exit Raises Questions Over Breyanzi Growth
- Negative Sentiment: Senior Vice President Phil Holzer sold 500 BMY shares for approximately $33,750, reducing his holdings by 2.88%. The small transaction is generally a limited signal, but may add modest caution after the stock’s recent advance. Bristol Myers Squibb SVP Sells 500 Shares
- Negative Sentiment: A patent dispute involving Cytokinetics creates additional legal uncertainty around BMY’s products and could increase future litigation or commercial risks. What Does Bristol Myers Squibb Face After Zenbexus Approval and Patent Action?
Bristol Myers Squibb Trading Down 0.9%
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. The firm had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The firm’s quarterly revenue was up 5.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, equities research analysts expect that Bristol Myers Squibb Company will post 6.95 EPS for the current year.
Bristol Myers Squibb Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 3.8%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is 55.51%.
Insider Transactions at Bristol Myers Squibb
In other news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the sale, the senior vice president owned 16,862 shares of the company’s stock, valued at $1,138,185. This represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.05% of the stock is currently owned by corporate insiders.
Analysts Set New Price Targets
Several analysts have commented on BMY shares. Truist Financial reaffirmed a “buy” rating and issued a $70.00 target price (up from $65.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. BMO Capital Markets reissued a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, July 27th. Bank of America decreased their price objective on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating on the stock in a report on Friday, July 10th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $59.00 target price (up from $54.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Finally, TD Cowen assumed coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a “buy” rating on the stock. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $66.06.
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.
BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.
Read More
- Five stocks we like better than Bristol Myers Squibb
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
